

Catherine Thieblemont

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7152991/catherine-thieblemont-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

318
papers

13,163
citations

60
h-index

109
g-index

345
ext. papers

16,418
ext. citations

5.6
avg, IF

5.95
L-index

#	Paper	IF	Citations
318	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. <i>Blood</i> , 2010 , 116, 2040-5	2.2	886
317	Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. <i>Nature Genetics</i> , 2014 , 46, 171-5	36.3	411
316	Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. <i>Blood</i> , 2000 , 95, 802-806	2.2	407
315	Treatment of older patients with mantle-cell lymphoma. <i>New England Journal of Medicine</i> , 2012 , 367, 520-31	59.2	368
314	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2003 , 102, 2741-5	2.2	324
313	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2011 , 12, 460-8	21.7	309
312	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology, the</i> , 2016 , 3, e196-204	14.6	270
311	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. <i>Lancet, The</i> , 2011 , 378, 1858-67	40	251
310	Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. <i>Blood</i> , 2000 , 95, 1950-1956	2.2	248
309	SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. <i>Blood</i> , 2011 , 118, 37-43	2.2	235
308	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet, The</i> , 2016 , 388, 565-75	40	233
307	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2013 , 24, 857-77	10.3	225
306	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncology, The</i> , 2014 , 15, 1019-26	21.7	215
305	The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4079-87	2.2	207
304	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1250-1260	59.2	205
303	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 525-33	21.7	200
302	CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007 , 25, 787-92	2.2	200

301	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1386-94	2.2	197
300	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1285-1295	2.2	188
299	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017 , 129, 2224-2232	2.2	184
298	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1188-1199	2.2	165
297	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013 , 24, 561-76	10.3	162
296	Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 565-72	2.2	161
295	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. <i>Blood</i> , 2012 , 119, 5126-32	2.2	159
294	Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2912-9	2.2	159
293	Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. <i>Annals of Oncology</i> , 2017 , 28, 2169-2178	10.3	157
292	Alteration of BIRC3 and multiple other NF-B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , 2011 , 118, 4930-4	2.2	151
291	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016 , 51, 51-7	4.4	149
290	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017 , 28, 1436-1447	10.3	148
289	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011 , 117, 1595-604	2.2	145
288	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. <i>Blood</i> , 2010 , 116, 1479-88	2.2	145
287	Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. <i>Lancet Oncology</i> , 2003 , 4, 95-103	21.7	137
286	Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2920-6	2.2	124
285	Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. <i>Clinical Lymphoma and Myeloma</i> , 2002 , 3, 41-7		124
284	MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. <i>Blood</i> , 2012 , 119, 4619-24	2.2	123

283	Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2009 , 100, 920-6	6.9	122
282	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3291-3299	2.2	116
281	Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1338-46	2.2	112
280	Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. <i>Blood</i> , 2010 , 116, 5119-25	2.2	107
279	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2473-2481	2.2	106
278	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015 , 126, 604-11	2.2	104
277	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2524-34	27.4	102
276	Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. <i>Blood</i> , 2015 , 126, 1695-8	2.2	99
275	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1905-1912	2.2	98
274	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. <i>Blood</i> , 2010 , 116, 1092-104	2.2	98
273	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2020 , 7, e511-e522	14.6	97
272	A MALT lymphoma prognostic index. <i>Blood</i> , 2017 , 130, 1409-1417	2.2	96
271	A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. <i>European Journal of Cancer</i> , 2013 , 49, 2869-76	7.5	88
270	Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. <i>PLoS ONE</i> , 2013 , 8, e55870	3.7	84
269	Clinical presentation and management of marginal zone lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2005 , 2005, 307-13	3.1	82
268	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , 2017 , 52, 216-221	4.4	77
267	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020 , 31, 17-29	10.3	77
266	Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. <i>Lancet Haematology</i> , 2015 , 2, e160-5	14.6	74

265	Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. <i>Nature Genetics</i> , 2018 , 50, 1650-1657	36.3	74
264	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. <i>American Journal of Hematology</i> , 2015 , 90, 197-203	7.1	72
263	Impact of the COVID-19 Outbreak on the Management of Patients with Cancer. <i>Targeted Oncology</i> , 2020 , 15, 249-259	5	65
262	Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase 3 trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3002-3010	2.2	64
261	Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. <i>British Journal of Haematology</i> , 2013 , 162, 489-97	4.5	63
260	Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. <i>Haematologica</i> , 2005 , 90, 470-8	6.6	62
259	Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 397-405	6.2	61
258	FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. <i>Blood</i> , 2017 , 130, 1315-1326	2.2	59
257	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1854-60	1.9	59
256	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 5607-5615	7.8	58
255	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. <i>Seminars in Cancer Biology</i> , 2014 , 24, 33-42	12.7	57
254	Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. <i>Annals of Oncology</i> , 2013 , 24, 1344-51	10.3	57
253	Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 43-54	3.2	52
252	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 399-406	18.8	52
251	Optimizing therapy for nodal marginal zone lymphoma. <i>Blood</i> , 2016 , 127, 2064-71	2.2	46
250	Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. <i>British Journal of Haematology</i> , 2014 , 166, 390-400	4.5	45
249	Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 262-9	2	43
248	Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <i>Leukemia</i> , 2018 , 32, 1799-1803	10.7	42

247	Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?. <i>Clinical Lymphoma and Myeloma</i> , 2005 , 5, 220-4		42
246	Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. <i>International Journal of Cancer</i> , 2015 , 136, 2761-74	7.5	41
245	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. <i>Blood</i> , 2020 , 135, 1396-1405	2.2	41
244	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015 , 125, 1922-31	2.2	40
243	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. <i>Annals of Oncology</i> , 2012 , 23, 2380-2385	10.3	40
242	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Regimen: the Randomized LSG11 Mantle Cell Lymphoma Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1149-53	2.2	40
241	GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF- κ B-dependent induction of HIF-1 β . <i>Leukemia</i> , 2015 , 29, 1163-76	10.7	39
240	A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016 , 173, 722-30	4.5	38
239	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015 , 20, 1149-53	5.7	37
238	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. <i>European Respiratory Journal</i> , 2016 , 47, 1244-60	13.6	37
237	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019 , 6, e429-e437	14.6	37
236	Efficacy of ibrutinib in the treatment of Bing-Neel syndrome. <i>American Journal of Hematology</i> , 2016 , 91, E17-9	7.1	37
235	Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. <i>Haematologica</i> , 2016 , 101, 336-45	6.6	37
234	Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. <i>Leukemia</i> , 2018 , 32, 2590-2603	10.7	36
233	Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016 , 27, 390-7	10.3	35
232	Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. <i>Blood</i> , 2016 , 128, 145-145	2.2	35
231	MALT lymphomas: pathogenesis can drive treatment. <i>Oncology</i> , 2011 , 25, 1134-42, 1147	1.8	35
230	Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. <i>Cancer</i> , 2005 , 104, 1434-41	6.4	32

229	Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 243-243	2.2	32
228	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1317-1328	2.2	32
227	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 1403-1415	21.7	32
226	Clinical aspects and therapy of gastrointestinal MALT lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017 , 30, 109-117	4.2	31
225	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. <i>Cell Metabolism</i> , 2019 , 29, 1243-1257.e10	24.6	31
224	Deep-Learning F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 30-36	8.9	31
223	Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2016 , 51, 365-71	4.4	30
222	Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 884-884	2.2	30
221	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016 , 91, 179-84	7.1	30
220	Targeting of B-cell receptor signalling in B-cell malignancies. <i>Journal of Internal Medicine</i> , 2017 , 282, 415-428	14.2	29
219	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 248-256	2.2	29
218	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2016 , 101, e407-e410	6.6	28
217	Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. <i>Annals of Oncology</i> , 2013 , 24, 2612-2618	10.3	27
216	NF-B in the New Era of Cancer Therapy. <i>Trends in Cancer</i> , 2020 , 6, 677-687	12.5	27
215	A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2863-9	1.9	26
214	Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). <i>Annals of Oncology</i> , 2013 , 24, 1032-7	10.3	26
213	Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. <i>Leukemia and Lymphoma</i> , 2003 , 44, 257-62	1.9	26
212	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.. <i>New England Journal of Medicine</i> , 2021 ,	59.2	26

211	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018 , 183, 755-765	4.5	25
210	Second-line treatment paradigms for diffuse large B-cell lymphomas. <i>Current Oncology Reports</i> , 2009 , 11, 386-93	6.3	24
209	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018 , 132, 1486-1494	2.2	21
208	MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?. <i>Blood</i> , 2013 , 121, 2165-6	2.2	21
207	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.. <i>New England Journal of Medicine</i> , 2021 ,	59.2	21
206	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma	2.2	21
205	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020 , 4, 5773-5784	7.8	20
204	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. <i>Haematologica</i> , 2020 , 105, e33-e36	6.6	20
203	Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. <i>Blood Cancer Journal</i> , 2020 , 10, 62	7	19
202	Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). <i>Digestive and Liver Disease</i> , 2018 , 50, 124-131	3.3	18
201	Treatment of follicular lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2014 , 54, 31-7	1.9	18
200	Splenic marginal zone lymphoma: current knowledge and future directions. <i>Oncology</i> , 2012 , 26, 194-202	1.8	18
199	Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. <i>OncoTargets and Therapy</i> , 2018 , 11, 2287-2293	4.4	17
198	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014 , 93, 233-42	3	17
197	Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies 2014 ,		17
196	Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. <i>Annals of Hematology</i> , 2015 , 94, 89-95	3	16
195	Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study. <i>Blood</i> , 2014 , 124, 146-146	2.2	16
194	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016 , 11, e0156384	3.7	16

193	G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2347-2349	4.4	16
192	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021 , 137, 2307-2320	2.2	16
191	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017 , 96, 253-259	3	15
190	At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. <i>European Journal of Immunology</i> , 2013 , 43, 1383-8	6.1	15
189	Non-MALT marginal zone lymphoma. <i>Current Opinion in Hematology</i> , 2011 , 18, 273-9	3.3	15
188	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf	2.2	15
187	Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/P) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study. <i>Blood</i> , 2021 , 138, 91-91	2.2	15
186	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1203-1213	2.2	15
185	Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1240-5	1.9	14
184	Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 151-4	2	14
183	Lenalidomide in diffuse large B-cell lymphoma. <i>Advances in Hematology</i> , 2012 , 2012, 861060	1.5	14
182	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. <i>Oncotarget</i> , 2016 , 7, 83987-84002	3.3	14
181	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017 , 28, 1042-1049	10.3	13
180	Optimizing initial therapy in DLBCL. <i>Best Practice and Research in Clinical Haematology</i> , 2018 , 31, 199-208	4.2	13
179	Discovery of Human-Similar Gene Fusions in Canine Cancers. <i>Cancer Research</i> , 2017 , 77, 5721-5727	10.1	13
178	A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018 , 132, 784-784	2.2	13
177	Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3067-3067	2.2	13
176	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019 , 134, 4103-4103	2.2	12

175	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 194, 690-700	4.5	12
174	Burden of illness of follicular lymphoma and marginal zone lymphoma. <i>Annals of Hematology</i> , 2019 , 98, 175-183	3	12
173	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. <i>Haematologica</i> , 2020 , 105, 2592-2597	6.6	11
172	Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. <i>Annals of Oncology</i> , 2016 , 27, 1349-50	10.3	11
171	Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2362-7	1.9	11
170	Human Herpesvirus-6 cytopathic inclusions: an exceptional and recognizable finding on skin biopsy during HHV6 reactivation after autologous stem-cell transplantation. <i>American Journal of Dermatopathology</i> , 2012 , 34, e73-6	0.9	11
169	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , 2018 , 132, 228-228	2.2	11
168	HHV-6 reactivation as a cause of fever in autologous hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2017 , 75, 155-159	18.9	11
167	Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. <i>Annals of Oncology</i> , 2017 , 28, 2680-2690	10.3	10
166	Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2019 , 125, 2291-2299	6.4	10
165	Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. <i>British Journal of Haematology</i> , 2014 , 166, 306-8	4.5	10
164	Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients. <i>Oncotarget</i> , 2017 , 8, 80073-80082	3.3	10
163	Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2017 , 2017, 371-378	3.1	10
162	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.. <i>Nature Medicine</i> , 2021 ,	50.5	10
161	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. <i>Blood</i> , 2016 , 128, 471-471	2.2	10
160	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2021 , JCO2101815	2.2	10
159	CD19-directed CAR T-cell therapy in B-cell NHL. <i>Current Opinion in Oncology</i> , 2020 , 32, 408-417	4.2	10
158	Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. <i>Journal of Dermatology</i> , 2021 , 48, e49-e71	1.6	10

157	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 21	22.4	9
156	Earlier Steroid Use with Axicabtagene Ciloleucl (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL). <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, S101	4.7	9
155	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019 , 17, 115	3	9
154	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018 , 132, 4196-4196	2.2	9
153	Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study. <i>Blood</i> , 2012 , 120, 152-152	2.2	9
152	Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. <i>Blood</i> , 2016 , 128, 1213-1213	2.2	9
151	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020 , 189, 84-96	4.5	9
150	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 6323-6332	12.9	9
149	Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006. <i>International Journal of Cancer</i> , 2015 , 137, 1217-23	7.5	8
148	Stabilization of β catenin upon B-cell receptor signaling promotes NF- κ B target genes transcription in mantle cell lymphoma. <i>Oncogene</i> , 2020 , 39, 2934-2947	9.2	8
147	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018 , 182, 807-815	4.5	8
146	Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 2023-30	8.8	8
145	Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation. <i>British Journal of Haematology</i> , 2013 , 162, 846-8	4.5	8
144	Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. <i>Oncotarget</i> , 2017 , 8, 16243-16258	3.3	8
143	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucl for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 195, 388-398	4.5	8
142	Axicabtagene ciloleucl as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. <i>Nature Medicine</i> , 2022 ,	50.5	8
141	Clinical features of life-threatening complications following autologous stem cell transplantation in patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3090-5	1.9	7
140	Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. <i>Cancer Medicine</i> , 2018 , 7, 539-548	4.8	7

139	Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial. <i>Blood</i> , 2020 , 136, 28-30	2.2	7
138	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , 2013 , 122, 764-764	2.2	7
137	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014 , 124, 4417-4417	2.2	7
136	A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma. <i>Blood</i> , 2014 , 124, 4458-4458	2.2	7
135	Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T phase IB trial of the LYSA. <i>Annals of Hematology</i> , 2020 , 99, 1771-1778	3	6
134	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. <i>European Respiratory Journal</i> , 2016 , 48, 1252	13.6	6
133	Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 827-839	1.5	6
132	Curing diffuse large B-cell lymphomas in elderly patients. <i>European Journal of Internal Medicine</i> , 2018 , 58, 14-21	3.9	6
131	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021 , 8, e648-e657	14.6	6
130	Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 237-244	3.2	5
129	PET2 -driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP. <i>British Journal of Haematology</i> , 2015 , 170, 278-81	4.5	5
128	Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa. <i>Blood</i> , 2019 , 134, 352-352	2.2	5
127	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2021 ,	2.2	5
126	Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. <i>British Journal of Haematology</i> , 2016 , 175, 735-737	4.5	5
125	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. <i>Bone Marrow Transplantation</i> , 2020 , 55, 613-622	4.4	5
124	Management of aggressive lymphoma in very elderly patients. <i>Hematological Oncology</i> , 2017 , 35 Suppl 1, 49-53	1.3	4
123	Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2025-31	1.9	4
122	Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study. <i>Annals of Hematology</i> , 2020 , 99, 1615-1625 ³		4

121	BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma. <i>Modern Pathology</i> , 2012 , 25, 805-14	9.8	4
120	Non-gastric extranodal marginal zone lymphomas: a challenge in routine practice. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2229-30	1.9	4
119	Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	4
118	Phase I/II Study of IPH1101, T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.. <i>Blood</i> , 2009 , 114, 1649-1649	2.2	4
117	An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,. <i>Blood</i> , 2011 , 118, 3715-3715	2.2	4
116	Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party. <i>Blood</i> , 2011 , 118, 473-473	2.2	4
115	Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 1532-1532	2.2	4
114	Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. <i>Lancet Haematology</i> , 2020 , 7, e798-e807	14.6	4
113	Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7508-7508	2.2	4
112	Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. <i>Haematologica</i> , 2021 , 106, 859-862	6.6	4
111	Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomenigeal dissemination. <i>Seminars in Hematology</i> , 2018 , 55, 179-181	4	4
110	Definition of a minimal genes set for mature lymphoid blood diseases. <i>Hematologie</i> , 2018 , 24, 27-59	0	4
109	Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1561-1572	7.4	3
108	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. <i>Annals of Hematology</i> , 2015 , 94, 1859-63	3	3
107	Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. <i>PharmacoEconomics - Open</i> , 2020 , 4, 575-591	2.1	3
106	Therapy-related classical Hodgkin lymphoma after a primary haematological malignancy: a report on 13 cases. <i>British Journal of Haematology</i> , 2012 , 158, 644-8	4.5	3
105	Interim-Positron Emission Tomography with [18F]Fluorodeoxyglucose (interim-PET) Evaluation In Mediastinal Lymphoma Including Hodgkin Lymphoma (HL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL). <i>Blood</i> , 2010 , 116, 2860-2860	2.2	3
104	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. <i>Blood</i> , 2011 , 118, 2632-2632	2.2	3

103	Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). <i>Blood</i> , 2011 , 118, 268-268	2.2	3
102	VEGF, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. <i>Oncotarget</i> , 2017 , 8, 90808-90824	3.3	3
101	Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2020 , 111, 409-416	2.3	3
100	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 111	22.4	3
99	Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma. <i>Annals of Hematology</i> , 2021 , 100, 979-986	3	3
98	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. <i>Cancer Research</i> , 2021 , 81, 5202-5216	10.1	3
97	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-1. Follicular lymphoma (FL). <i>International Journal of Hematology</i> , 2019 , 110, 11-19	2.3	2
96	Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1135-43	3.5	2
95	A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B-Cell Lymphoma in Need of Systemic Therapy. <i>Blood</i> , 2018 , 132, 446-446	2.2	2
94	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018 , 132, 922-922 ^{2,2}	2.2	2
93	Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. <i>Blood</i> , 2018 , 132, 1677-1677	2.2	2
92	Subgroup Analyses of Elderly Patients Aged ≥70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2019 , 134, 347-347	2.2	2
91	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy. <i>Blood</i> , 2011 , 118, 2718-2718 ^{2,2}	2.2	2
90	A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study. <i>Blood</i> , 2012 , 120, 1617-1617	2.2	2
89	Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas. <i>Blood</i> , 2021 , 138, 1433-1433	2.2	2
88	Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021 , 138, 739-739	2.2	2
87	Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. <i>Journal of Infection</i> , 2020 , 80, 219-224	18.9	2
86	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2371-2381	6.1	2

85	Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort. <i>British Journal of Haematology</i> , 2020 , 191, e90-e94	4.5	2
84	Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization. <i>American Journal of Hematology</i> , 2021 , 96, E311-E314 ²	7.1	2
83	Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome. <i>Annals of Hematology</i> , 2019 , 98, 195-203	3	2
82	New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT. <i>Cancers</i> , 2021 , 13,	6.6	2
81	A guide to ComBat harmonization of imaging biomarkers in multicenter studies. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	2
80	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021 , 13,	6.6	2
79	Comparing apples and oranges : the ZUMA-7, TRANSFORM and BELINDA trials.. <i>Hematological Oncology</i> , 2022 ,	1.3	2
78	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.. <i>Leukemia and Lymphoma</i> , 2022 , 1-11	1.9	2
77	Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. <i>Leukemia and Lymphoma</i> , 2020 , 61, 887-895	1.9	1
76	Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?. <i>British Journal of Haematology</i> , 2018 , 180, 304-308	4.5	1
75	Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study. <i>Japanese Journal of Clinical Oncology</i> , 2018 , 48, 736-742	2.8	1
74	Treatment for patients with indolent and mantle cell lymphoma. <i>Lancet, The</i> , 2013 , 382, 1094	4.0	1
73	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.. <i>Cancers</i> , 2022 , 14,	6.6	1
72	A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 5310-5310	2.2	1
71	Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. <i>Blood</i> , 2014 , 124, 1625-1625	2.2	1
70	Promising Results of Ibrutinib in Three Patients with Secondary Central Nervous System Mantle Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3105-3105	2.2	1
69	Analytical Performance of Nanostring's Companion Diagnostic (CDx) Lymphoma Subtyping Test (LST) with Diffuse Large B-Cell Lymphoma Core Needle Biopsy Samples. <i>Blood</i> , 2015 , 126, 1481-1481	2.2	1
68	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , 2015 , 126, 517-517 ²	1.7	1

67	Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T3 Phase IB Trial of the Lysa Group. <i>Blood</i> , 2016 , 128, 2987-2987	2.2	1
66	Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8503-8503	2.2	1
65	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2021 , 138, 3528-3528	2.2	1
64	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021 , 138, 131-131	2.2	1
63	Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6). <i>Blood</i> , 2021 , 138, 2832-2832	2.2	1
62	A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry. <i>Blood</i> , 2021 , 138, 92-92	2.2	1
61	Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2021 , 138, 306-306	2.2	1
60	Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. <i>Blood</i> , 2021 , 138, LBA-6-LBA-6	2.2	1
59	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , 2014 , 124, 2526-2526	2.2	1
58	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1700-1709	4.4	1
57	Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2021 , 17, 1295-1310	3.6	1
56	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7544-7544	2.2	1
55	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. <i>Cancer Medicine</i> , 2021 , 10, 5101-5109	4.8	1
54	IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019 , 37, 244-245	1.3	1
53	Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21). <i>Journal of Physical Education and Sports Management</i> , 2021 , 7,	2.8	1
52	Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials.. <i>Leukemia and Lymphoma</i> , 2022 , 1-12	1.9	1
51	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group. <i>Hematological Oncology</i> , 2020 , 38, 446-455	1.3	0
50	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.. <i>Leukemia and Lymphoma</i> , 2022 , 1-12	1.9	0

49	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7518-7518	2.2	o
48	Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry. <i>Blood</i> , 2021 , 138, 885-885	2.2	o
47	Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Results of the Selinda Phase Ib Lysa Study. <i>Blood</i> , 2021 , 138, 1411-1411	2.2	o
46	Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). <i>Blood</i> , 2021 , 138, 430-430	2.2	o
45	Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021 , 13, 1453-1465	3.4	o
44	Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis.. <i>Blood</i> , 2008 , 112, 1780-1780	2.2	o
43	Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network. <i>British Journal of Haematology</i> , 2021 , 193, 1110-1122	4.5	o
42	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Soci� Francophone de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>American Journal of Hematology</i> , 2021 , 96, 834-845	7.1	o
41	CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7543-7543	2.2	o
40	Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors. <i>Haematologica</i> , 2021 , 106, 593-596	6.6	o
39	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021 , 5, 2965-2968	7.8	o
38	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022 , 6, e726	0.3	o
37	Mantle Cell Lymphoma 2015 , 233-243		
36	Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2425-8	1.9	
35	Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , 2014 , 164, 896-9	4.5	
34	H�matologie maligne, Chicago 2012. <i>Oncologie</i> , 2012 , 14, 478-480	1	
33	Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial. <i>Blood</i> , 2020 , 136, 42-42	2.2	
32	A Retrospective Study of 67 Inflammatory Waldenstr�m's Macroglobulinemia. <i>Blood</i> , 2020 , 136, 14-15	2.2	

31	What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts.. <i>HemaSphere</i> , 2022 , 6, e680	0.3
30	Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma 2022 , 119-122	
29	A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa. <i>Blood</i> , 2021 , 138, 3495-3495	2.2
28	A Systematic Review and a Survey Both Reveal Wide Heterogeneity across Trials and Investigators on Time-to-Event Endpoints Definitions in Marginal Zone Lymphoma. <i>Blood</i> , 2021 , 138, 4502-4502	2.2
27	Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study. <i>Blood</i> , 2021 , 138, 3533-3533	2.2
26	Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy In Study By the Lysa Group. <i>Blood</i> , 2018 , 132, 4099-4099	2.2
25	Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2018 , 132, 2846-2846	2.2
24	Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study. <i>Blood</i> , 2018 , 132, 4199-4199	2.2
23	Hepatitis B Virus Associated B-Cell Non-Hodgkin Lymphoma in Non-Endemic Areas. <i>Blood</i> , 2018 , 132, 4228-4228	2.2
22	Germline TIM-3 Mutations Characterize Sub-Cutaneous Panniculitis T-Cell Lymphomas with Hemophagocytic Lymphohistiocytic Syndrome. <i>Blood</i> , 2018 , 132, 1569-1569	2.2
21	A multicenter study of 66 patients with spinal cord compression at diagnosis of B-cell non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8560-8560	2.2
20	Meta-analysis of the risk of secondary neoplasm in patients treated for non-Hodgkin lymphoma with rituximab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19541-e19541	2.2
19	Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study. <i>Blood</i> , 2014 , 124, 1657-1657	2.2
18	Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?. <i>Blood</i> , 2015 , 126, 2886-2886	2.2
17	Metabolic Tumor Volume Influences Response to Brentuximab-Vedotin in Relapsed Refractory Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 588-588	2.2
16	Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies. <i>Blood</i> , 2016 , 128, 927-927	2.2
15	Tolerance and Efficacy of L-Asparaginase during Induction of Extra-Nodal Natural Killer (NK/T) Lymphoma, Nasal Type, in Real-Life Experience. <i>Blood</i> , 2016 , 128, 5351-5351	2.2
14	Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL). <i>Blood</i> , 2011 , 118, 2673-2673	2.2

- 13 The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. *Blood*, **2011**, 118, 502-502 2.2
- 12 Lymphoma Occurring Over the Age of 90: Clinical Presentation and Outcome. *Blood*, **2012**, 120, 1582-1582
- 11 Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03BB GELA Study.. *Blood*, **2012**, 120, 2723-2723
- 10 Hairy Cell Leukemia: Evaluation of Long-Term Outcomes in 487 Patients. *Blood*, **2012**, 120, 3921-3921 2.2
- 9 Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. *Blood*, **2013**, 122, 3005-3005 2.2
- 8 Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. *Blood*, **2013**, 122, 2202-2202 2.2
- 7 Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. *Blood*, **2013**, 122, 77-77 2.2
- 6 Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. *Blood*, **2013**, 122, 3663-3663 2.2
- 5 Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases. *Blood*, **2013**, 122, 5308-5308 2.2
- 4 CD5-negative blastoid variant mantle cell lymphoma: a diagnostic dilemma. *Human Pathology*, **2021**, 111, 84-91 3.7
- 3 Aspects biologiques et thérapeutiques des lymphomes de la zone marginale. *Revue Francophone Des Laboratoires*, **2021**, 2021, 56-63 0
- 2 Splenic Marginal Zone Lymphoma. *Hematologic Malignancies*, **2021**, 127-142 0
- 1 Finding a consensus on time-to-event endpoints definitions in Marginal Zone Lymphoma: a Delphi method.. *Hematological Oncology*, **2022**, 1.3